UBA1 and proximal spinal muscular atrophy: Here, we demonstrate that ubiquitin pathway defects represent a key driver of both neuromuscular and systemic pathology in SMA, with targeting of UBA1 representing a safe and effective approach for developing novel and effective SMN-independent therapies.